-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Orthopoxvirus
- Others
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Virus Protease
- Antiviral intermediates
Dolutegravir-d3
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/dolutegravir-d3.gif)
| Category | HIV Integrase |
| Description | Dolutegravir-d3 (S/GSK1349572-d3) is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC50 of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC50 of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC50 =3.6-5.8 nM). |
Product Information
| Synonyms | Dolutegravir-D3|AKOS037652726|ES-2483|HY-13238S1|CS-0372435 |
| Molecular Weight | 422.4 |
| Molecular Formula | C20H19F2N3O5 |
| Canonical SMILES | CC1CCOC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O |
| Boiling Point | 664.9±55.0 °C(Predicted) |
| Purity | 99.7% by HPLC |
| Density | 1.53±0.1 g/cm3(Predicted) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | 2-8°C Refrigerator |
| Complexity | 829 |
| Exact Mass | 422.14810728 |
| In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and Metabolic profiles of drugs. |
| Target | HIV Integrase; HIV |
| XLogP3-AA | 2.4 |
